Product
AT
1 clinical trial
1 indication
Indication
Triple-negative Breast CancerClinical trial
A Prospective, Open, Single-arm, Phase Ⅱ Clinical Study of Anlotinib Combined With Tislelizumab and AT in the Neoadjuvant Treatment of Triple-negative Breast CancerStatus: Recruiting, Estimated PCD: 2025-03-31